Nampt (Visfatin/PBEF) (human) ELISA Kit
AG-45A-0006YTP
Product group Assays
Overview
- SupplierAdipoGen Life Sciences
- Product NameNampt (Visfatin/PBEF) (human) ELISA Kit
- Delivery Days Customer10
- ApplicationsELISA
- Assay Detection Range0.125 to 8ng/ml
- Assay Sensitivity30pg/ml
- Assay SpecificityDetects human Nampt. Weakly cross-reacts (<15%) with mouse Nampt and rat Nampt. Does not cross-react with human adiponectin, human resistin, human vaspin or human RBP4. Has been shown to specifically detect the physiologically relevant Nampt dimer in huma
- CertificationResearch Use Only
- Scientific DescriptionELISA Assay. Detects human Nampt. Weakly cross-reacts (<15%) with mouse Nampt and rat Nampt. Does not cross-react with human adiponectin, human resistin, human vaspin or human RBP4. Has been shown to specifically detect the physiologically relevant Nampt dimer in human serum samples. Colorimetric assay. Sample Types: Serum. Range: 0.125 to 8ng/ml. Sensitivity: 30pg/ml. Nicotinamide phosphoribosyltransferase (Nampt; pre-B cell colony-enhancing factor; PBEF; Visfatin) is an 52kDA adipokine secreted by adipose tissue and involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). Two forms of Nampt exist, an intracellular form (iNampt) and an extracellular form (eNampt). While the function of iNampt as an essential and rate-limiting NAD+ biosynthetic enzyme is well established, the physiological role of eNampt is still a matter of debate. It has been shown that Nampt expression is increased in different diseases, like diabetes, obesity, fetal growth retardation, sepsis, inflammatory bowel disease, Crohns disease and rheumatoid arthritis. Furthermore, Nampt might be a marker of pre-eclampsia and of endothelial health. Recently it was reported that Visfatin levels were higher in the unstable carotid atherosclerotic plaque than in non-atherosclerotic mammary artery secretomes, suggesting a possible link between visfatin and unstable carotid atherosclerotic plaque. - Nicotinamide phosphoribosyltransferase (Nampt; pre-B cell colony-enhancing factor; PBEF; Visfatin) is an 52kDA adipokine secreted by adipose tissue and involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). Two forms of Nampt exist, an intracellular form (iNampt) and an extracellular form (eNampt). While the function of iNampt as an essential and rate-limiting NAD+ biosynthetic enzyme is well established, the physiological role of eNampt is still a matter of debate. It has been shown that Nampt expression is increased in different diseases, like diabetes, obesity, fetal growth retardation, sepsis, inflammatory bowel disease, Crohns disease and rheumatoid arthritis. Furthermore, Nampt might be a marker of pre-eclampsia and of endothelial health. Recently it was reported that Visfatin levels were higher in the unstable carotid atherosclerotic plaque than in non-atherosclerotic mammary artery secretomes, suggesting a possible link between visfatin and unstable carotid atherosclerotic plaque. Recently NAMPT extracellular (eNAMPT) has been shown to be secreted from macrophages in muscles and to triggers a proliferative signal of muscle stem cell (MusC) by binding to CCR5 located at the surface receptor of MusC.
- Storage Instruction2°C to 8°C
- UNSPSC41116158
References
- Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway: T. Yonezawa, et al.; FEBS Lett. 580, 6635 (2006)
- Molecular characteristics of serum visfatin and differential detection by immunoassays: A. Koerner, et al.; J. Clin. Endocrinol. Metab. 92, 4783 (2007)
- Serum levels of the adipokine visfatin are increased in pre-eclampsia: M. Fasshauer, et al.; Clin. Endocrinol. 69, 69 (2008)
- Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a cross-sectional study: R. Retnakaran, et al.; Clin. Endocrinol. 69, 885 (2008)
- Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery: M. M. Swarbrick, et al.; Diabetologia 51, 1901 (2008)
- Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis: M. Ziegelmeier, et al.; Metabolism 57, 1414 (2008)
- Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy: A.A. Alghasham & Y.A. Barakat; Saudi Med. J. 29, 185 (2008)
- Ethnic-specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function: M. Reimann, et al.; Obesity 17, 2210 (2009)
- Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis: F. Lovren, et al.; Am. J. Physiol. Endocrinol. Metab. 296, E1440 (2009)
- Circulating visfatin in chronic obstructive pulmonary disease: X. Liu, et al.; Nutrition 25, 373 (2009)